DE69111642D1 - Gabapentin und dessen Derivate zur Behandlung neurodegenerativer Krankheiten. - Google Patents
Gabapentin und dessen Derivate zur Behandlung neurodegenerativer Krankheiten.Info
- Publication number
- DE69111642D1 DE69111642D1 DE69111642T DE69111642T DE69111642D1 DE 69111642 D1 DE69111642 D1 DE 69111642D1 DE 69111642 T DE69111642 T DE 69111642T DE 69111642 T DE69111642 T DE 69111642T DE 69111642 D1 DE69111642 D1 DE 69111642D1
- Authority
- DE
- Germany
- Prior art keywords
- gabapentin
- derivatives
- treatment
- neurodegenerative diseases
- huntington
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45991290A | 1990-01-02 | 1990-01-02 | |
US07/615,151 US5084479A (en) | 1990-01-02 | 1990-11-23 | Novel methods for treating neurodegenerative diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69111642D1 true DE69111642D1 (de) | 1995-09-07 |
DE69111642T2 DE69111642T2 (de) | 1996-01-25 |
Family
ID=27039510
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69111642T Expired - Fee Related DE69111642T2 (de) | 1990-01-02 | 1991-01-02 | Gabapentin und dessen Derivate zur Behandlung neurodegenerativer Krankheiten. |
Country Status (7)
Country | Link |
---|---|
US (1) | US5084479A (de) |
EP (1) | EP0446570B1 (de) |
JP (1) | JP2903434B2 (de) |
AT (1) | ATE125701T1 (de) |
DE (1) | DE69111642T2 (de) |
DK (1) | DK0446570T3 (de) |
HK (1) | HK1005166A1 (de) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5025035A (en) * | 1990-10-12 | 1991-06-18 | Warner-Lambert Company | Method of treating depression |
US5217957A (en) * | 1991-08-20 | 1993-06-08 | Warner-Lambert Company | Cholecystokinin antagonists useful for treating depression |
US5792796A (en) * | 1994-07-27 | 1998-08-11 | Warner-Lambert Company | Methods for treating anxiety and panic |
US5510381A (en) * | 1995-05-15 | 1996-04-23 | Warner-Lambert Company | Method of treatment of mania and bipolar disorder |
PL185991B1 (pl) * | 1996-03-14 | 2003-09-30 | Warner Lambert Co | Nowe podstawione cykliczne aminokwasy i kompozycja farmaceutyczna |
US6372792B1 (en) | 1996-04-26 | 2002-04-16 | Guy Chouinard | Method for treating anxiety, anxiety disorders and insomnia |
PL189872B1 (pl) | 1996-07-24 | 2005-10-31 | Warner Lambert Co | Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu |
JP3963488B2 (ja) * | 1997-06-30 | 2007-08-22 | メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツンク ウント コンパニー コマンディゲゼルシャフト アウフ アクチェン | 1−アミノ−アルキルシクロヘキサンnmda受容体拮抗薬 |
AU9019198A (en) | 1997-08-19 | 1999-03-08 | Warner-Lambert Company | Methods for treating physiological conditions associated with the use, or sequelae of use, of ***e or other psychomotor stimulants |
AU9318398A (en) | 1997-10-07 | 1999-04-27 | Warner-Lambert Company | Process for preparing a cyclic amino acid anticonvulsant compound |
HUP0004310A3 (en) | 1997-10-27 | 2001-11-28 | Warner Lambert Co | Cyclic amino acids, and derivatives thereof and pharmaceutical compositions comprising the said compounds as active agents |
DE19751062A1 (de) * | 1997-11-18 | 1999-07-08 | Univ Ludwigs Albert | An 4-Stellung substituierte 2-Pyrrolidinon-Derivate zur Verringerung des extrazellulären Glutamat-Spiegels |
US6984659B2 (en) | 1997-11-18 | 2006-01-10 | Klinikum Der Albert-Ludwigs Universitaet | 2-pyrrolidinone derivatives substituted at position 4 for reducing the extracellular glutamate level |
KR100669280B1 (ko) * | 1998-05-15 | 2007-01-17 | 워너-램버트 캄파니 엘엘씨 | 감마-아미노부티르산 유도체 포함 고상 조성물 및 그의제조 방법 |
PT1077692E (pt) * | 1998-05-15 | 2004-12-31 | Warner Lambert Co | Preparacoes farmaceuticas estabilizadas de derivados do acido aminobutirico e processos para a sua preparacao |
US6294198B1 (en) * | 1999-08-24 | 2001-09-25 | Purepac Pharmaceutical Co. | Pharmaceutical tablet formulation containing gabapentin with improved physical and chemical characteristics and method of making the same |
US6350768B1 (en) | 1999-11-24 | 2002-02-26 | Aventis Pharma S.A. | Combination of riluzole and of gabapentin and its use as a medicament |
FR2801217B1 (fr) * | 1999-11-24 | 2002-12-06 | Aventis Pharma Sa | Association de riluzole et de gabapentine et son utilisation comme medicament |
CA2411787C (en) * | 2000-06-16 | 2007-03-20 | Teva Pharmaceuticals Industries Ltd. | Stable gabapentin having ph within a controlled range |
WO2001097612A1 (en) | 2000-06-16 | 2001-12-27 | Teva Pharmaceutical Industries Ltd. | Stable gabapentin containing more than 2o ppm of chlorine ion |
EP1296671B1 (de) * | 2000-06-26 | 2008-03-26 | Warner-Lambert Company LLC | Gabapentinanaloga für schlafstörungen |
US7056951B2 (en) | 2000-09-26 | 2006-06-06 | Mutual Pharmaceutical Co., Inc. | Stable solid dosage forms of amino acids and processes for producing same |
US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
HUP0400167A3 (en) * | 2001-06-11 | 2012-09-28 | Xenoport Inc | Prodrugs of gaba analogs, compositions and uses thereof |
US7232924B2 (en) * | 2001-06-11 | 2007-06-19 | Xenoport, Inc. | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs |
JP2005501013A (ja) * | 2001-06-11 | 2005-01-13 | ゼノポート,インコーポレイテッド | Gaba類似体の全身濃度が持続するアミノ酸コンジュゲート |
US6818787B2 (en) * | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US20060159743A1 (en) * | 2001-10-25 | 2006-07-20 | Depomed, Inc. | Methods of treating non-nociceptive pain states with gastric retentive gabapentin |
US7612112B2 (en) * | 2001-10-25 | 2009-11-03 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
US20070184104A1 (en) * | 2001-10-25 | 2007-08-09 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
ITMI20012750A1 (it) | 2001-12-21 | 2003-06-21 | Procos Spa | Processo per la produzione dell'acido 1-(amminometil)-cicloesil-acetico in forma pura |
US20030119908A1 (en) * | 2001-12-21 | 2003-06-26 | Zambon Group S.P.A. | Stable gabapentin compositions |
EP1471909A4 (de) * | 2002-01-16 | 2007-07-25 | Endo Pharmaceuticals Inc | Pharmazeutische zusammensetzung und verfahren zur behandlung von erkrankungen des zentralen nervensystems |
EP1485082A4 (de) | 2002-02-19 | 2009-12-30 | Xenoport Inc | Syntheseverfahren für prodrugs von 1-acyl-alkyl derivaten und ihre zusammensetzungen |
WO2003089403A1 (en) * | 2002-04-16 | 2003-10-30 | Taro Pharmaceutical Industries Ltd. | Process for preparing gabapentin |
WO2003099338A2 (en) * | 2002-05-17 | 2003-12-04 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
WO2004052360A1 (en) | 2002-12-11 | 2004-06-24 | Xenoport, Inc. | Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof |
US20040162351A1 (en) * | 2002-12-11 | 2004-08-19 | Gallop Mark A. | Orally administered dosage forms of fused GABA analog prodrugs having reduced toxicity |
CA2451267A1 (en) * | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
WO2005000294A1 (en) * | 2003-06-06 | 2005-01-06 | Pharmacia Corporation | Selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders |
SG146643A1 (en) | 2003-09-17 | 2008-10-30 | Xenoport Inc | Treating or preventing restless legs syndrome using prodrugs of gaba analogs |
SG147437A1 (en) | 2003-10-14 | 2008-11-28 | Xenoport Inc | Crystalline form of gamma-aminobutyric acid analog |
WO2005082372A1 (en) * | 2004-01-29 | 2005-09-09 | Pfizer Products Inc. | COMBINATION OF γ-AMINOBUTYRIC ACID MODULATORS AND 5-HT 1B RECEPTOR ANTAGONISTS |
US20050187295A1 (en) * | 2004-02-19 | 2005-08-25 | Surendra Kalyan | Processes for the preparation of gabapentin |
ITMI20040579A1 (it) * | 2004-03-25 | 2004-06-25 | Zambon Spa | Processo di preparazione di gabapentina |
BRPI0517227B8 (pt) | 2004-11-04 | 2021-05-25 | Xenoport Inc | comprimido oral de liberação prolongada do ácido 1-{[alfa-isobutanoiloxietoxi)carbonil]amino metil}-1-cicloexano acético, e, uso do comprimido |
US20090176882A1 (en) | 2008-12-09 | 2009-07-09 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
EP2575798B1 (de) | 2010-06-01 | 2017-08-09 | Rubicon Research Private Limited | Gastroretentive dosierungszubereitung von gaba analoga |
EP2923694B1 (de) | 2014-03-27 | 2018-11-14 | Sanovel Ilac Sanayi ve Ticaret A.S. | Orale flüssige pharmazeutische lösung von gabapentin |
CA3159067A1 (en) * | 2019-10-25 | 2021-04-29 | Kyoto University | Preventative or therapeutic agent for tauopathy |
CN115350172A (zh) * | 2022-08-12 | 2022-11-18 | 昆明医科大学 | Gabapentin对AD情景记忆改善的应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2460891C2 (de) * | 1974-12-21 | 1982-09-23 | Gödecke AG, 1000 Berlin | 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
-
1990
- 1990-11-23 US US07/615,151 patent/US5084479A/en not_active Expired - Lifetime
- 1990-12-27 JP JP2418309A patent/JP2903434B2/ja not_active Expired - Fee Related
-
1991
- 1991-01-02 DK DK91100109.7T patent/DK0446570T3/da active
- 1991-01-02 DE DE69111642T patent/DE69111642T2/de not_active Expired - Fee Related
- 1991-01-02 EP EP91100109A patent/EP0446570B1/de not_active Expired - Lifetime
- 1991-01-02 AT AT91100109T patent/ATE125701T1/de not_active IP Right Cessation
-
1998
- 1998-05-15 HK HK98104232A patent/HK1005166A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DK0446570T3 (da) | 1995-11-27 |
EP0446570A2 (de) | 1991-09-18 |
DE69111642T2 (de) | 1996-01-25 |
US5084479A (en) | 1992-01-28 |
JP2903434B2 (ja) | 1999-06-07 |
EP0446570B1 (de) | 1995-08-02 |
HK1005166A1 (en) | 1998-12-24 |
JPH04210915A (ja) | 1992-08-03 |
EP0446570A3 (en) | 1992-04-01 |
ATE125701T1 (de) | 1995-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69111642T2 (de) | Gabapentin und dessen Derivate zur Behandlung neurodegenerativer Krankheiten. | |
UY26813A1 (es) | Compuestos para tratar enfermedad de alzheimer | |
DE60112942D1 (de) | Verbindungen zur behandlung der alzheimerischen krankheit | |
DE69942702D1 (de) | Zusammenstellungen und methoden zur behandlung der alzheimerschen krankheit, schäden des zentralnervensystems und entzündlichen erkrankungen | |
DE60124085D1 (de) | Pde-v hemmer zur behandlung von morbus parkinson | |
DE3856594D1 (de) | Mittel zur behandlung der alzheimer-krankheit | |
BR9502707A (pt) | Composto composição farmacêutica e método para o tratamento de uma afecção | |
NO20083956L (no) | Prodrugs av GABA-analoger, sammensetninger og anvendelse derav | |
TW229156B (de) | ||
DE69716810T2 (de) | 2,3-Disubstituierte-(5,6)-heteroarylkondensierte-pyrimidin-4-one | |
ES2194960T3 (es) | N-(2-sustituido-3-(2-aminoetil)-1h-indol-5-il)-amidas como nuevos agonistas de 5-ht1f. | |
NZ234672A (en) | N-(1,2,3,4-tetrahydro-9-acridinyl)amide and carbamate derivatives and pharmaceutical compositions | |
ATE526981T1 (de) | Verwendung von vegf 165 und homologen zur behandlung von neurologischen störungen | |
ATE268337T1 (de) | C11-carbamate von antibakteriellen makroliden | |
EA200000242A1 (ru) | Применение фанхинона для лечения болезни альцгеймера | |
DE3854121T2 (de) | Arzneimittelzusammensetzungen zur behandlung von psoriasis. | |
ATE180669T1 (de) | Verwendung von pregnanderivaten zur behandlung von tumoren | |
ATE225171T1 (de) | Aminosäurederivate zur behandlung von schlaganfall | |
ATE239470T1 (de) | Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen | |
DE69911689D1 (de) | Verfahren zur Herstellung von S-Aryl-L-cystein und Derivate | |
DE69424415T2 (de) | Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit | |
DE69916577D1 (de) | Azetidincarboxamid-derivate zur behandlung von zns störungen | |
ATE323690T1 (de) | Bicyclische(3.1.0)hexane und verwandte verbindungen | |
HUT56559A (en) | Process for producing ascorbinic acid derivatives and pharma | |
ATE137973T1 (de) | Phospholipide zur behandlung der multiplen sklerose |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |